Skip to content

Clinical Evaluation of the Accuracy of Vitastiq Device for Tracking Vitamin and Mineral Trend in Human Body

Clinical Evaluation of the Accuracy of Vitastiq Device for Tracking Vitamin and Mineral Trend in Human Body

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03399240
Acronym
VITASTIQ
Enrollment
45
Registered
2018-01-16
Start date
2017-05-17
Completion date
2017-11-02
Last updated
2018-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No Conditions

Brief summary

This is a single site evaluation study of Vitastiq device accuracy in healthy men and women in ratio 1:1 (approximately) aged between 18 and 64 years. A total of 45 Vitastiq personal devices will be used by volunteers for two months. The Vitastiq device will be evaluated during three site visits: on day 1, 29 ± 4 days and 57 ± 4 days. During site visit days, blood sampling will be collected and analysed and readings using Vitastiq device will be performed. Data will be analysed retrospectively to evaluate Vitastiq performance compared to blood tests results.

Interventions

DEVICEVitasitiq device

Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.

Sponsors

MEDEDUS, Ljubljana, Slovenia
CollaboratorUNKNOWN
Adria Lab, Ljubljana, Slovenia
CollaboratorUNKNOWN
Vizera d.o.o.
CollaboratorINDUSTRY
Faculty of Pharmacy, Ljubljana, Slovenia
CollaboratorUNKNOWN
Vitastiq d.o.o.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* Informed consent form (ICF) is signed by a volunteer * Age between 18 and 64 years at the time of the signature of ICF * A body mass index (BMI) between 18 and 28 kg/m2 * Healthy, meaning absence of any chronic or acute medical therapy for a month prior to the inclusion to the study * Willing to follow all study procedures, including attending all site visits, and keeping a food diary and diary of activities on a weekly basis

Exclusion criteria

* Intake of any drugs to treat chronic disease within 1 month before the beginning and during the study * Intake of any drugs to treat serious acute disease within 1 month before the beginning of the study and within 5 days of each visit * Any clinically significant medical history of serious digestive tract, liver, kidney, skin or haematological disease or hormone imbalance * Pregnant and breastfeeding women * Women who planning pregnancy during the study * Inadequate veins (in the opinion of the investigator) * Known drug or alcohol abuse * Using any form of nicotine or tobacco * Mental incapacity that precludes adequate understanding or cooperation * Participation in another investigational study or blood donation within 3 months prior to or during this study

Design outcomes

Primary

MeasureTime frameDescription
Vitastiq device accuracy and performance30 minutesVitastiq accuracy performance is at least 70% meaning that at least 70% of Vitastiq readings for each mineral and vitamin fall within the range of matching blood test results.

Secondary

MeasureTime frameDescription
Vitastiq readings method is repeatable30 minutesVitastiq readings method is at least 80% repeatable. It means that at least 80% of Vitastiq readings for each mineral and vitamin performed by investigators and participant in the time frame of 30 minutes are comparable.

Countries

Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026